SQUARE PHARMS PLC
GenericsSQUARE PHARMS PLC is a generic drug manufacturer focused on Neurology.
SQUARE PHARMS PLC's Key Drugs
SQUARE PHARMS PLC's core commercial portfolio centers on CALCIUM CHLORIDE 10%, spanning Neurology — its most strategically important drugs approved in the last 15 years.
SQUARE PHARMS PLC's Recent FDA Approvals
New NDA/BLA approvals for SQUARE PHARMS PLC over the last two years — novel drugs only, excluding generics and label supplements.
SQUARE PHARMS PLC's Therapeutic Areas
SQUARE PHARMS PLC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SQUARE PHARMS PLC's Top Competitors
SQUARE PHARMS PLC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SQUARE PHARMS PLC Pipeline Snapshot
Active clinical trials for SQUARE PHARMS PLC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CALCIUM CHLORIDE 10% leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-06-01
- Latest
- 2026-07-09
- Applications
- 5